Sermorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It stimulates the pituitary gland to release endogenous growth hormone (GH), which then increases IGF-1 levels.
Sermorelin (formerly marketed as Geref) was previously FDA-approved for diagnosing and treating growth hormone deficiency in children.
However:
Sermorelin, although similar to Tesamorelin, has a shorter half life and a milder response.
Most clinical research involving sermorelin focused on growth hormone deficiency diagnostics in children. Evidence supporting use in healthy adults for anti-aging or body composition remains limited.
Example NIH / PubMed Studies on Sermorelin
This study evaluated sermorelin as a diagnostic tool for growth hormone deficiency by stimulating GH release.
Researchers assessed sermorelin's ability to stimulate GH secretion in pediatric patients with suspected GH deficiency.
Examined the use of GHRH analogs (including sermorelin) in long-term treatment of growth hormone deficiency.
If you're using a browser with advanced ad blocking security measures, the above study links may not work. You can copy the link and paste it into a new window.
Disclaimer: The information on this page was generated with the assistance of artificial intelligence and compiled from publicly available sources. While efforts are made to ensure accuracy, information may be incomplete, outdated, or incorrect and should not be relied upon as medical advice.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded drugs have not been approved by the FDA; have not been reviewed by the FDA for safety, efficacy, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The processes by which the compounded drugs are manufactured have not been reviewed by the FDA. FDA approved products containing semaglutide and tirzepatide are available.